Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2 Completed 10 enrolled M.D. Anderson Cancer Center Novartis Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.

Timeline

Start: 2007-04
Primary completion: 2009-10
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	10 mg	Oral

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Summary

Timeline

Drugs

Indications